Previous close | 128.65 |
Open | 128.05 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 126.70 - 129.75 |
52-week range | 65.40 - 129.75 |
Volume | |
Avg. volume | 300,347 |
Market cap | 24.462B |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | 73.24 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.36 (1.06%) |
Ex-dividend date | 26 Apr 2024 |
1y target est | N/A |
UCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).1 This article represents the primary publication of BIMZELX data from the two pivotal Phase 3 HS studies. HS is one of the most burdensome, chronic, systemic, inflammatory s
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
UCB, a global biopharmaceutical company, today announced the launch of Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.